Purpose of Review

To provide a highlight of the current state of cell therapy for the treatment of critical limb ischemia in patients with diabetes.

Recent Findings

The global incidence of diabetes is constantly growing with consequent challenges for healthcare systems worldwide. In the UK only, NHS costs attributed to diabetic complications, such as peripheral vascular disease, amputation, blindness, renal failure, and stroke, average £10 billion each year, with cost pressure being estimated to get worse. Although giant leaps forward have been registered in the scope of early diagnosis and optimal glycaemic control, an effective treatment for critical limb ischemia is still lacking. The present review aims to provide an update of the ongoing work in the field of regenerative medicine. Recent advancements but also limitations imposed by diabetes on the potential of the approach are addressed. In particular, the review focuses on the perturbation of non-coding RNA networks in progenitor cells and the possibility of using emerging knowledge on molecular mechanisms to design refined protocols for personalized therapy.

Summary

The field of cell therapy showed rapid progress but has limitations. Significant advances are foreseen in the upcoming years thanks to a better understanding of molecular bottlenecks associated with the metabolic disorders.

中文翻译：

---

临界肢体缺血的细胞疗法：优势，局限性，和治疗糖尿病性严重血管病患者的新观点。

审查目的

为突出显示目前用于治疗糖尿病患者严重肢体缺血的细胞疗法的现状。

最近的发现

全球糖尿病的发病率一直在增长，随之而来的是全球医疗系统的挑战。仅在英国，NHS的成本就归因于糖尿病并发症，例如周围血管疾病，截肢，失明，肾衰竭和中风，每年平均100亿英镑，而成本压力估计会进一步恶化。尽管已经在早期诊断和最佳血糖控制范围内取得了巨大的飞跃，但仍缺乏有效的治疗肢体缺血的方法。本综述旨在提供有关再生医学领域正在进行的工作的最新信息。不仅解决了糖尿病的最新进展，而且还限制了糖尿病对这种方法的潜力的限制。特别是，

概括

细胞治疗领域显示出快速的进步，但是有局限性。由于对与代谢紊乱有关的分子瓶颈有了更好的了解，因此在未来几年中有望取得重大进展。